Is Agape ATP going out of business? ATPC cash runway

Loading the full analysis

Reading the filings

Agape ATP Corp (ATPC) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Agape ATP Corp (ATPC) scores 13 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Quality score 13/100

Rating Distressed / Caution

Sector Biotech/Pharma

Market cap $2.2M

Last close $2.24

Revenue growth (YoY) -20.3%

FCF margin (TTM) -287.5%

Dividend yield 0.0%

Leading signal: ROIC: -14.17%

Survival - Critical: Under 1 mo of estimated runway from 2026-06-30, based on $45.5K of cash and short-term investments against $3.3M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.
Business quality - Pre-commercial: Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.
Trajectory - Clinical progress unavailable: Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.
Valuation - Extreme expectations: -0.8% net-cash backing support an extreme expectations pre-commercial Valuation assessment.
Event risk - Critical event risk: Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 2 scanned filings. Favorable events are shown separately and do not offset adverse risk.

Read from filings through 2026-08-14.

Price as of 2026-09-26.

Source coverage and limitations

Reference Links